The Stalair(R) r Bet v 1 tablet (birch pollen recombinant allergen) has been the subject of a positive phase IIb/III clinical trial conducted in allergic rhinitis caused by birch pollen. A confirmatory phase III study is currently being prepared with a view to EMA registration.
The ragweed pollen and Japanese cedar pollen tablets are at an early stage of development.
Altogether, the program covers 80% of the epidemiology for all markets.
ABOUT SHIONOGI & CO.,LTD
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp.
Stallergenes is a European biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma.
A pioneer and leader in sublingual immunotherapy treatments, Stallergenes
dedicates more than 20% of its turnover, in gross terms, to Research and
Development and is actively involved in the development of a new therapeutic
Copyright©2010 PR Newswire.
All rights reserved